Details of the Drug

General Information of Drug (ID: DMR6QH0)

• Drug Name: Venlafaxine
• Synonyms: Efectin; Elafax; Venlafaxina; VenlafaxineXR; Venlafaxinum; Venlafaxine ER; Wy 45030; Efectin (TN); Venlafaxina [INN-Spanish];Venlafaxine (Effexor); Venlafaxine (INN); Venlafaxine [BAN:INN]; Venlafaxine [INN:BAN]; Venlafaxinum [INN-Latin]; N,N-dimethyl-2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethylamine; 1-[(1R)-2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; 1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Approved	[1]
Depression	6A70-6A7Z	Approved	[2]
Major depressive disorder	6A70.3	Approved	[1]
Panic disorder	6B01	Approved	[1]

• Therapeutic Class: Antidepressants
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 277.4
  Logarithm of the Partition Coefficient (xlogp); 2.9
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 152.6 mcgh/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 352.8 mcg/L [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: The bioavailability of drug is 10% [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [5]
  Elimination: 4.6% of drug is excreted from urine in the unchanged form [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5 hours [5]
  Metabolism: The drug is metabolized via the liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.5868 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.73% [5]
  Vd: The volume of distribution (Vd) of drug is 7.5 +/- 3.7 L/kg []
  Water Solubility: The ability of drug to dissolve in water is measured as 572 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Nausea and vomiting symptoms	rs5030655	CYP2D6	OTZJC802	[7]
Venlafaxine	rs2032583	ABCB1	OTEJROBO	[8]

• Chemical Identifiers:
  Formula: C17H27NO2
  IUPAC Name: 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol
  Canonical SMILES: CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
  InChI: InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3
  InChIKey: PNVNVHUZROJLTJ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5656
  ChEBI ID: CHEBI:9943
  CAS Number: 93413-69-5
  DrugBank ID: DB00285
  TTD ID: D0P1UX
  VARIDT ID: DR00450
  INTEDE ID: DR1679
  ACDINA ID: D00725
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[9]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[12]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[12]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[8]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[7]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 06 Mental, behavioural or neurodevelopmental disorder
• Disease Class: ICD-11: 6A20 Schizophrenia
• The Studied Tissue: Pre-frontal cortex
• The Studied Disease: Major depressive disorder [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Norepinephrine transporter (NET)	DTT	SLC6A2	7.05E-01	7.02E-03	0.07
Serotonin transporter (SERT)	DTT	SLC6A4	1.17E-01	0.07	0.59
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	7.66E-01	9.19E-03	4.88E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	7.83E-01	2.32E-03	1.53E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Venlafaxine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aprepitant	DM053KT	Moderate	Decreased metabolism of Venlafaxine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[13]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Venlafaxine and Sertraline.	Depression [6A70-6A7Z]	[14]
Trimipramine	DM1SC8M	Major	Additive serotonergic effects by the combination of Venlafaxine and Trimipramine.	Depression [6A70-6A7Z]	[14]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Venlafaxine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[14]
Imipramine	DM2NUH3	Major	Additive serotonergic effects by the combination of Venlafaxine and Imipramine.	Depression [6A70-6A7Z]	[14]
Fluoxetine	DM3PD2C	Major	Additive serotonergic effects by the combination of Venlafaxine and Fluoxetine.	Depression [6A70-6A7Z]	[14]
Nortriptyline	DM4KDYJ	Major	Additive serotonergic effects by the combination of Venlafaxine and Nortriptyline.	Depression [6A70-6A7Z]	[14]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Venlafaxine and Vilazodone.	Depression [6A70-6A7Z]	[14]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Venlafaxine and Nefazodone.	Depression [6A70-6A7Z]	[14]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Venlafaxine and Paroxetine.	Depression [6A70-6A7Z]	[14]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Venlafaxine and Selegiline.	Depression [6A70-6A7Z]	[15]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Venlafaxine and Vortioxetine.	Depression [6A70-6A7Z]	[14]
Duloxetine	DM9BI7M	Major	Additive serotonergic effects by the combination of Venlafaxine and Duloxetine.	Depression [6A70-6A7Z]	[14]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Venlafaxine and Isocarboxazid.	Depression [6A70-6A7Z]	[15]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Venlafaxine and Milnacipran.	Depression [6A70-6A7Z]	[14]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Escitalopram.	Depression [6A70-6A7Z]	[16]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Venlafaxine and Tranylcypromine.	Depression [6A70-6A7Z]	[15]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Venlafaxine and Desvenlafaxine.	Depression [6A70-6A7Z]	[14]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Venlafaxine and Phenelzine.	Depression [6A70-6A7Z]	[15]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Venlafaxine and Clomipramine.	Depression [6A70-6A7Z]	[14]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Venlafaxine and Trazodone.	Depression [6A70-6A7Z]	[14]
Amitriptyline	DMK7F9S	Major	Additive serotonergic effects by the combination of Venlafaxine and Amitriptyline.	Depression [6A70-6A7Z]	[14]
Amoxapine	DMKITQE	Major	Additive serotonergic effects by the combination of Venlafaxine and Amoxapine.	Depression [6A70-6A7Z]	[14]
Mirtazapine	DML53ZJ	Major	Additive serotonergic effects by the combination of Venlafaxine and Mirtazapine.	Depression [6A70-6A7Z]	[14]
Protriptyline	DMNHTZI	Major	Additive serotonergic effects by the combination of Venlafaxine and Protriptyline.	Depression [6A70-6A7Z]	[14]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Venlafaxine and Doxepin.	Depression [6A70-6A7Z]	[14]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Venlafaxine and Maprotiline.	Depression [6A70-6A7Z]	[14]

Coadministration of a Drug Treating the Disease Different from Venlafaxine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Venlafaxine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[17]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[18]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Midostaurin.	Acute myeloid leukaemia [2A60]	[19]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Idarubicin.	Acute myeloid leukaemia [2A60]	[19]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[19]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Arn-509.	Acute myeloid leukaemia [2A60]	[20]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[21]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Oliceridine.	Acute pain [MG31]	[22]
Epinephrine	DM3KJBC	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Epinephrine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[23]
Terfenadine	DM4KLPT	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Tacrine.	Alzheimer disease [8A20]	[19]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Galantamine.	Alzheimer disease [8A20]	[19]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Rivastigmine.	Alzheimer disease [8A20]	[19]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Donepezil.	Alzheimer disease [8A20]	[19]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Venlafaxine and Metronidazole.	Amoebiasis [1A36]	[13]
Inotersen	DMJ93CT	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Inotersen.	Amyloidosis [5D00]	[24]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Ivabradine.	Angina pectoris [BA40]	[20]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Bepridil.	Angina pectoris [BA40]	[19]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Dronedarone.	Angina pectoris [BA40]	[19]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Venlafaxine caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[13]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[25]
Methylphenobarbital	DMDSWAG	Moderate	Antagonize the effect of Venlafaxine when combined with Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[26]
Promazine	DMZAL7W	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Promazine.	Appearance/behaviour symptom [MB23]	[19]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Venlafaxine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[13]
Levalbuterol	DM5YBO1	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Levalbuterol.	Asthma [CA23]	[23]
Terbutaline	DMD4381	Moderate	Additive hypertensive effects by the combination of Venlafaxine and Terbutaline.	Asthma [CA23]	[23]
Pirbuterol	DMI5678	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Pirbuterol.	Asthma [CA23]	[23]
Ephedrine	DMMV0KW	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Ephedrine.	Asthma [CA23]	[23]
Salbutamol	DMN9CWF	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Salbutamol.	Asthma [CA23]	[23]
Formoterol	DMSOURV	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Formoterol.	Asthma [CA23]	[23]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Venlafaxine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[14]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Venlafaxine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Venlafaxine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Venlafaxine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[19]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Chloramphenicol	DMFXEWT	Moderate	Decreased metabolism of Venlafaxine caused by Chloramphenicol mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Venlafaxine and Linezolid.	Bacterial infection [1A00-1C4Z]	[28]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Venlafaxine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Venlafaxine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Retigabine	DMGNYIH	Moderate	Antagonize the effect of Venlafaxine when combined with Retigabine.	Behcet disease [4A62]	[26]
Lamotrigine	DM8SXYG	Moderate	Antagonize the effect of Venlafaxine when combined with Lamotrigine.	Bipolar disorder [6A60]	[26]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Venlafaxine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[29]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Loperamide.	Bowel habit change [ME05]	[30]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Eribulin.	Breast cancer [2C60-2C6Y]	[19]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Lapatinib.	Breast cancer [2C60-2C6Y]	[19]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Venlafaxine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Venlafaxine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[19]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Toremifene.	Breast cancer [2C60-2C6Y]	[19]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[31]
Pseudoephedrine	DMIVJ0D	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Pseudoephedrine.	Breathing abnormality [MD11]	[23]
Mannitol	DMSCDY9	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Mannitol.	Bronchiectasis [CA24]	[32]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Grepafloxacin.	Bronchitis [CA20]	[27]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Sotalol.	Cardiac arrhythmia [BC9Z]	[19]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[33]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Venlafaxine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Vilanterol	DMF5EK1	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Salmeterol	DMIEU69	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Indacaterol	DMQJHR7	Moderate	Additive hypertensive effects by the combination of Venlafaxine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Arformoterol	DMYM974	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Phenylbutazone.	Chronic pain [MG30]	[24]
Ketoprofen	DMRKXPT	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Ketoprofen.	Chronic pain [MG30]	[24]
Morphine	DMRMS0L	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Morphine.	Chronic pain [MG30]	[22]
Levetiracetam	DMTGDN8	Moderate	Antagonize the effect of Venlafaxine when combined with Levetiracetam.	Chronic pain [MG30]	[26]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Venlafaxine and Levomilnacipran.	Chronic pain [MG30]	[14]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Anisindione.	Coagulation defect [3B10]	[24]
Regorafenib	DMHSY1I	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Regorafenib.	Colorectal cancer [2B91]	[24]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Oxaliplatin.	Colorectal cancer [2B91]	[19]
Isoproterenol	DMK7MEY	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Isoproterenol.	Conduction disorder [BC63]	[23]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Venlafaxine and Olopatadine.	Conjunctiva disorder [9A60]	[34]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Propofol.	Corneal disease [9A76-9A78]	[35]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Sevoflurane.	Corneal disease [9A76-9A78]	[19]
Alfentanil	DMVO0UB	Major	Additive serotonergic effects by the combination of Venlafaxine and Alfentanil.	Corneal disease [9A76-9A78]	[14]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Probucol.	Coronary atherosclerosis [BA80]	[19]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Ardeparin.	Coronary thrombosis [BA43]	[24]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Methadone.	Cough [MD12]	[19]
Dextromethorphan	DMUDJZM	Major	Additive serotonergic effects by the combination of Venlafaxine and Dextromethorphan.	Cough [MD12]	[14]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Clofazimine.	Crohn disease [DD70]	[36]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Pasireotide.	Cushing syndrome [5A70]	[19]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Osilodrostat.	Cushing syndrome [5A70]	[20]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Venlafaxine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[13]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Venlafaxine and Ethanol.	Cystitis [GC00]	[34]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Venlafaxine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[13]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Danaparoid.	Deep vein thrombosis [BD71]	[24]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Rivaroxaban.	Deep vein thrombosis [BD71]	[24]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Venlafaxine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[23]
LEVONORDEFRIN	DMWDJ0H	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and LEVONORDEFRIN.	Discovery agent [N.A.]	[23]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[19]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Deutetrabenazine.	Dystonic disorder [8A02]	[37]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Ingrezza.	Dystonic disorder [8A02]	[38]
Fenfluramine	DM0762O	Major	Additive serotonergic effects by the combination of Venlafaxine and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[14]
Zonisamide	DM0DTF7	Moderate	Antagonize the effect of Venlafaxine when combined with Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[26]
Felbamate	DM1V5ZS	Moderate	Antagonize the effect of Venlafaxine when combined with Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[26]
Oxcarbazepine	DM5PU6O	Moderate	Antagonize the effect of Venlafaxine when combined with Oxcarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[26]
Mephenytoin	DM5UGDK	Moderate	Antagonize the effect of Venlafaxine when combined with Mephenytoin.	Epilepsy/seizure [8A61-8A6Z]	[26]
Methsuximide	DM6L5VO	Moderate	Antagonize the effect of Venlafaxine when combined with Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[26]
Gabapentin	DM6T924	Moderate	Antagonize the effect of Venlafaxine when combined with Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[26]
Valproate	DMCFE9I	Moderate	Antagonize the effect of Venlafaxine when combined with Valproate.	Epilepsy/seizure [8A61-8A6Z]	[26]
Ethosuximide	DMDZ9LT	Moderate	Antagonize the effect of Venlafaxine when combined with Ethosuximide.	Epilepsy/seizure [8A61-8A6Z]	[26]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Venlafaxine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Tiagabine	DMKSQG0	Moderate	Antagonize the effect of Venlafaxine when combined with Tiagabine.	Epilepsy/seizure [8A61-8A6Z]	[26]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Venlafaxine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[13]
Phenacemide	DMOHS9P	Moderate	Antagonize the effect of Venlafaxine when combined with Phenacemide.	Epilepsy/seizure [8A61-8A6Z]	[26]
Paramethadione	DMR5ZUP	Moderate	Antagonize the effect of Venlafaxine when combined with Paramethadione.	Epilepsy/seizure [8A61-8A6Z]	[26]
Brivaracetam	DMSEPK8	Moderate	Antagonize the effect of Venlafaxine when combined with Brivaracetam.	Epilepsy/seizure [8A61-8A6Z]	[26]
Lacosamide	DMVM6QR	Moderate	Antagonize the effect of Venlafaxine when combined with Lacosamide.	Epilepsy/seizure [8A61-8A6Z]	[26]
Ethotoin	DMXWOCP	Moderate	Antagonize the effect of Venlafaxine when combined with Ethotoin.	Epilepsy/seizure [8A61-8A6Z]	[26]
Vigabatrin	DMYT0OG	Moderate	Antagonize the effect of Venlafaxine when combined with Vigabatrin.	Epilepsy/seizure [8A61-8A6Z]	[26]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[26]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Ethacrynic acid.	Essential hypertension [BA00]	[32]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Bendroflumethiazide.	Essential hypertension [BA00]	[32]
Mephentermine	DMFJH5Q	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Mephentermine.	Essential hypertension [BA00]	[23]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Benzthiazide.	Essential hypertension [BA00]	[32]
Oxymetazoline	DM8ZXT6	Moderate	Additive hypertensive effects by the combination of Venlafaxine and Oxymetazoline.	Eyelid inflammatory disorder [9A02]	[23]
Phenylephrine	DMZHUO5	Moderate	Additive hypertensive effects by the combination of Venlafaxine and Phenylephrine.	Faecal incontinence [ME07]	[23]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Mefenamic acid.	Female pelvic pain [GA34]	[24]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Tazemetostat.	Follicular lymphoma [2A80]	[24]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Solifenacin.	Functional bladder disorder [GC50]	[19]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Pentamidine.	Fungal infection [1F29-1F2F]	[19]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Venlafaxine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[40]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Venlafaxine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Venlafaxine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Cimetidine	DMH61ZB	Minor	Decreased metabolism of Venlafaxine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[41]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[19]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[19]
Avapritinib	DMK2GZX	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[24]
Acetazolamide	DM1AF5U	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Acetazolamide.	Glaucoma [9C61]	[32]
Methazolamide	DM7J2TA	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Methazolamide.	Glaucoma [9C61]	[32]
Dipivefrin	DMH5W0G	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Dipivefrin.	Glaucoma [9C61]	[23]
Dichlorphenamide	DMH7IDQ	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Dichlorphenamide.	Glaucoma [9C61]	[32]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Sulfinpyrazone.	Gout [FA25]	[24]
Ergotamine	DMKR3C5	Major	Additive serotonergic effects by the combination of Venlafaxine and Ergotamine.	Headache [8A80-8A84]	[14]
Spironolactone	DM2AQ5N	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Spironolactone.	Heart failure [BD10-BD1Z]	[32]
Triamterene	DM2HU9I	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Triamterene.	Heart failure [BD10-BD1Z]	[32]
Dobutamine	DMD1B8Z	Moderate	Additive hypertensive effects by the combination of Venlafaxine and Dobutamine.	Heart failure [BD10-BD1Z]	[23]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[32]
Furosemide	DMMQ8ZG	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Furosemide.	Heart failure [BD10-BD1Z]	[32]
Amiloride	DMRTSGP	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Amiloride.	Heart failure [BD10-BD1Z]	[32]
Bumetanide	DMRV7H0	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Bumetanide.	Heart failure [BD10-BD1Z]	[32]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[32]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Venlafaxine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[13]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Venlafaxine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[13]
Tetrahydrozoline	DMT57WC	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Tetrahydrozoline.	Herpes simplex infection [1F00]	[23]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Venlafaxine caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[13]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Venlafaxine and Procarbazine.	Hodgkin lymphoma [2B30]	[15]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Venlafaxine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Venlafaxine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[42]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Venlafaxine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Venlafaxine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Venlafaxine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Venlafaxine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Venlafaxine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Venlafaxine caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[13]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Venlafaxine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[13]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Venlafaxine caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[13]
Diltiazem	DMAI7ZV	Moderate	Decreased metabolism of Venlafaxine caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[13]
Methoxamine	DMF5XQH	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Methoxamine.	Hypertension [BA00-BA04]	[23]
Indapamide	DMGN1PW	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Indapamide.	Hypertension [BA00-BA04]	[32]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Trichlormethiazide.	Hypertension [BA00-BA04]	[32]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[32]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Dipyridamole.	Hypertension [BA00-BA04]	[24]
Metaraminol	DMWIX23	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Metaraminol.	Hypotension [BA20-BA21]	[23]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[31]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Venlafaxine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[45]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Venlafaxine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[19]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[19]
Naphazoline	DMJFZDL	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Naphazoline.	Itching [1F28-1G07]	[23]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Venlafaxine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[20]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Crizotinib.	Lung cancer [2C25]	[46]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Venlafaxine and Porfimer Sodium.	Lung cancer [2C25]	[47]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Ceritinib.	Lung cancer [2C25]	[19]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Venlafaxine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[48]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Osimertinib.	Lung cancer [2C25]	[49]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Selpercatinib.	Lung cancer [2C25]	[20]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Lumefantrine.	Malaria [1F40-1F45]	[13]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Halofantrine.	Malaria [1F40-1F45]	[50]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Chloroquine.	Malaria [1F40-1F45]	[51]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Quinine.	Malaria [1F40-1F45]	[19]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Primaquine.	Malaria [1F40-1F45]	[19]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[20]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Venlafaxine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Venlafaxine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[52]
Acalabrutinib	DM7GCVW	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[24]
Ibrutinib	DMHZCPO	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Ibrutinib.	Mature B-cell lymphoma [2A85]	[24]
Ponatinib	DMYGJQO	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Ponatinib.	Mature B-cell lymphoma [2A85]	[24]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Vemurafenib.	Melanoma [2C30]	[19]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and LGX818.	Melanoma [2C30]	[53]
Danazol	DML8KTN	Moderate	Decreased metabolism of Venlafaxine caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[13]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Venlafaxine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[54]
Zolmitriptan	DM1IB4Q	Major	Additive serotonergic effects by the combination of Venlafaxine and Zolmitriptan.	Migraine [8A80]	[14]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Venlafaxine and Almogran.	Migraine [8A80]	[14]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Venlafaxine and Frovatriptan.	Migraine [8A80]	[14]
Rizatriptan	DMDJMA3	Major	Additive serotonergic effects by the combination of Venlafaxine and Rizatriptan.	Migraine [8A80]	[14]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Venlafaxine and Naratriptan.	Migraine [8A80]	[14]
Sumatriptan	DMVYXR8	Major	Additive serotonergic effects by the combination of Venlafaxine and Sumatriptan.	Migraine [8A80]	[14]
Exjade	DMHPRWG	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Exjade.	Mineral absorption/transport disorder [5C64]	[24]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Venlafaxine and Flibanserin.	Mood disorder [6A60-6E23]	[55]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Panobinostat.	Multiple myeloma [2A83]	[56]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Venlafaxine and Thalidomide.	Multiple myeloma [2A83]	[57]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Siponimod.	Multiple sclerosis [8A40]	[13]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Fingolimod.	Multiple sclerosis [8A40]	[19]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Ozanimod.	Multiple sclerosis [8A40]	[15]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Romidepsin.	Mycosis fungoides [2B01]	[19]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Venlafaxine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[19]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[24]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Venlafaxine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Dasatinib	DMJV2EK	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[24]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Prasugrel.	Myocardial infarction [BA41-BA43]	[24]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Vorapaxar.	Myocardial infarction [BA41-BA43]	[24]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Tirofiban.	Myocardial infarction [BA41-BA43]	[24]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Droperidol.	Nausea/vomiting [MD90]	[19]
Prochlorperazine	DM53SRA	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Prochlorperazine.	Nausea/vomiting [MD90]	[19]
Palonosetron	DMBHMOX	Major	Additive serotonergic effects by the combination of Venlafaxine and Palonosetron.	Nausea/vomiting [MD90]	[19]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Granisetron.	Nausea/vomiting [MD90]	[19]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Dolasetron.	Nausea/vomiting [MD90]	[19]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Ondansetron.	Nausea/vomiting [MD90]	[19]
E-2007	DMJDYNQ	Moderate	Antagonize the effect of Venlafaxine when combined with E-2007.	Neuropathy [8C0Z]	[26]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Entrectinib.	Non-small cell lung cancer [2C25]	[13]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Venlafaxine and Sibutramine.	Obesity [5B80-5B81]	[58]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Venlafaxine and Lorcaserin.	Obesity [5B80-5B81]	[59]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Venlafaxine and Dexfenfluramine.	Obesity [5B80-5B81]	[14]
Propylhexedrine	DMTBW2O	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Propylhexedrine.	Obesity [5B80-5B81]	[23]
Chlorthalidone	DM4DMBT	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Chlorthalidone.	Oedema [MG29]	[32]
Metolazone	DMB39LO	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Metolazone.	Oedema [MG29]	[32]
Polythiazide	DMCH80F	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Polythiazide.	Oedema [MG29]	[32]
Urea	DMUK75B	Moderate	Increased risk of hyponatremia by the combination of Venlafaxine and Urea.	Oesophagitis [DA24]	[32]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[20]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Venlafaxine and Lofexidine.	Opioid use disorder [6C43]	[19]
Diclofenac	DMPIHLS	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Diclofenac.	Osteoarthritis [FA00-FA05]	[24]
Naproxen	DMZ5RGV	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Naproxen.	Osteoarthritis [FA00-FA05]	[24]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Rucaparib.	Ovarian cancer [2C73]	[19]
Pentazocine	DM1XBHS	Major	Additive serotonergic effects by the combination of Venlafaxine and Pentazocine.	Pain [MG30-MG3Z]	[14]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Venlafaxine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[60]
Butorphanol	DM5KYPJ	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Butorphanol.	Pain [MG30-MG3Z]	[22]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Oxymorphone.	Pain [MG30-MG3Z]	[22]
Aspirin	DM672AH	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Aspirin.	Pain [MG30-MG3Z]	[31]
Etodolac	DM6WJO9	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Etodolac.	Pain [MG30-MG3Z]	[24]
Diflunisal	DM7EN8I	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Diflunisal.	Pain [MG30-MG3Z]	[24]
Ibuprofen	DM8VCBE	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Ibuprofen.	Pain [MG30-MG3Z]	[24]
Nabumetone	DMAT2XH	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Nabumetone.	Pain [MG30-MG3Z]	[24]
Levorphanol	DMGS80V	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Levorphanol.	Pain [MG30-MG3Z]	[22]
Hydromorphone	DMHP21E	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Hydromorphone.	Pain [MG30-MG3Z]	[22]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Venlafaxine and Dezocine.	Pain [MG30-MG3Z]	[22]
Codeine	DMJX6ZG	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Codeine.	Pain [MG30-MG3Z]	[22]
Nalbuphine	DMOSQGU	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Nalbuphine.	Pain [MG30-MG3Z]	[22]
Buprenorphine	DMPRI8G	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Buprenorphine.	Pain [MG30-MG3Z]	[22]
Piroxicam	DMTK234	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Piroxicam.	Pain [MG30-MG3Z]	[24]
Meperidine	DMX4GND	Major	Additive serotonergic effects by the combination of Venlafaxine and Meperidine.	Pain [MG30-MG3Z]	[14]
Oxycodone	DMXLKHV	Moderate	Additive serotonergic effects by the combination of Venlafaxine and Oxycodone.	Pain [MG30-MG3Z]	[22]
Trimethadione	DM0Q8MZ	Moderate	Antagonize the effect of Venlafaxine when combined with Trimethadione.	Pancreatic cancer [2C10]	[26]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Triclabendazole.	Parasitic worm infestation [1F90]	[19]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Venlafaxine and Safinamide.	Parkinsonism [8A00]	[15]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Venlafaxine and Rasagiline.	Parkinsonism [8A00]	[15]
Dopamine	DMPGUCF	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Dopamine.	Parkinsonism [8A00]	[23]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Pimavanserin.	Parkinsonism [8A00]	[61]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Apomorphine.	Parkinsonism [8A00]	[19]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Venlafaxine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[62]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Venlafaxine and Lindane.	Pediculosis [1G00]	[63]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Famotidine.	Peptic ulcer [DA61]	[13]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[64]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[24]
Ketorolac	DMI4EL5	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Ketorolac.	Postoperative inflammation [1A00-CA43]	[24]
Bromfenac	DMKB79O	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Bromfenac.	Postoperative inflammation [1A00-CA43]	[24]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Venlafaxine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[13]
Ritodrine	DM4V6RL	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Ritodrine.	Preterm labour/delivery [JB00]	[23]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Degarelix.	Prostate cancer [2C82]	[20]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Venlafaxine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[65]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Nilutamide.	Prostate cancer [2C82]	[20]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Enzalutamide.	Prostate cancer [2C82]	[20]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Venlafaxine caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[13]
Alfuzosin	DMZVMKF	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Alfuzosin.	Prostate hyperplasia [GA90]	[19]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[19]
Triflupromazine	DMKFQJP	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[19]
Treprostinil	DMTIQF3	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Treprostinil.	Pulmonary hypertension [BB01]	[24]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Epoprostenol.	Pulmonary hypertension [BB01]	[24]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Iloprost.	Pulmonary hypertension [BB01]	[24]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Sorafenib.	Renal cell carcinoma [2C90]	[19]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[66]
Meloxicam	DM2AR7L	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Meloxicam.	Rheumatoid arthritis [FA20]	[24]
Sulindac	DM2QHZU	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Sulindac.	Rheumatoid arthritis [FA20]	[24]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Venlafaxine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[67]
Oxaprozin	DM9UB0P	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Oxaprozin.	Rheumatoid arthritis [FA20]	[24]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Flurbiprofen.	Rheumatoid arthritis [FA20]	[24]
Fenoprofen	DML5VQ0	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Fenoprofen.	Rheumatoid arthritis [FA20]	[24]
Indomethacin	DMSC4A7	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Indomethacin.	Rheumatoid arthritis [FA20]	[24]
Tolmetin	DMWUIJE	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Tolmetin.	Rheumatoid arthritis [FA20]	[24]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Quetiapine.	Schizophrenia [6A20]	[19]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Mesoridazine.	Schizophrenia [6A20]	[19]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Thioridazine.	Schizophrenia [6A20]	[19]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Iloperidone.	Schizophrenia [6A20]	[19]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Perphenazine.	Schizophrenia [6A20]	[19]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Chlorpromazine.	Schizophrenia [6A20]	[19]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Clozapine.	Schizophrenia [6A20]	[19]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Trifluoperazine.	Schizophrenia [6A20]	[19]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Risperidone.	Schizophrenia [6A20]	[19]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Amisulpride.	Schizophrenia [6A20]	[68]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Asenapine.	Schizophrenia [6A20]	[19]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Pimozide.	Schizophrenia [6A20]	[20]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[31]
Norepinephrine	DMOUC09	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Norepinephrine.	Sepsis [1G40-1G41]	[23]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[19]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Venlafaxine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[13]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Venlafaxine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[20]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Venlafaxine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
LEE011	DMMX75K	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[13]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[19]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[19]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[19]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Venlafaxine caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[20]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[19]
Warfarin	DMJYCVW	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Warfarin.	Supraventricular tachyarrhythmia [BC81]	[24]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[19]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Venlafaxine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[19]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Venlafaxine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[69]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Caplacizumab.	Thrombocytopenia [3B64]	[24]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Apixaban.	Thrombosis [DB61-GB90]	[24]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Cangrelor.	Thrombosis [DB61-GB90]	[24]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Brilinta.	Thrombosis [DB61-GB90]	[24]
Clopidogrel	DMOL54H	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Clopidogrel.	Thrombosis [DB61-GB90]	[24]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Lenvatinib.	Thyroid cancer [2D10]	[19]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Papaverine.	Tonus and reflex abnormality [MB47]	[70]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Tizanidine.	Tonus and reflex abnormality [MB47]	[19]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Tacrolimus.	Transplant rejection [NE84]	[19]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[19]
Xylometazoline	DMKV32D	Moderate	Increased risk of rapid heart rate by the combination of Venlafaxine and Xylometazoline.	Vasomotor/allergic rhinitis [CA08]	[23]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Venlafaxine and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[71]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Venlafaxine and Betrixaban.	Venous thromboembolism [BD72]	[24]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Venlafaxine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[19]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[19]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Venlafaxine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[19]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Cetostearyl alcohol	E00353	62238	Emollient; Emulsifying agent; Viscosity-controlling agent
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dibutyl sebacate	E00160	7986	Plasticizing agent
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Medium-chain triglyceride	E00640	Not Available	Emollient; Lubricant; Surfactant
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Ethyl cellulose	E00699	Not Available	Coating agent; Microencapsulating agent; Binding agent; Diluent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Venlafaxine 150 mg tablet	150 mg	24 HR Extended Release Oral Tablet	Oral
Venlafaxine 225 mg tablet	225 mg	24 HR Extended Release Oral Tablet	Oral
Venlafaxine 37.5 mg tablet	37.5 mg	24 HR Extended Release Oral Tablet	Oral
Venlafaxine 75 mg tablet	75 mg	24 HR Extended Release Oral Tablet	Oral
Venlafaxine 37.5 mg capsule	37.5 mg	24 HR Extended Release Oral Capsule	Oral
Venlafaxine 75 mg capsule	75 mg	24 HR Extended Release Oral Capsule	Oral
Venlafaxine 150 mg capsule	150 mg	24 HR Extended Release Oral Capsule	Oral
Venlafaxine 37.5 mg capsule	37.5 mg	24 HR Extended Release Capsule	Oral
Venlafaxine 75 mg capsule	75 mg	24 HR Extended Release Capsule	Oral
Venlafaxine 150 mg capsule	150 mg	24 HR Extended Release Capsule	Oral
Venlafaxine 100 mg tablet	100 mg	Oral Tablet	Oral
Venlafaxine 25 mg tablet	25 mg	Oral Tablet	Oral
Venlafaxine 37.5 mg tablet	37.5 mg	Oral Tablet	Oral
Venlafaxine 50 mg tablet	50 mg	Oral Tablet	Oral
Venlafaxine 75 mg tablet	75 mg	Oral Tablet	Oral
Venlafaxine Hydrochloride eq 12.5mg base tablet	eq 12.5mg base	Tablet	Oral
Venlafaxine Hydrochloride eq 37.5mg base extended release capsule	eq 37.5mg base	Extended Release Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Venlafaxine FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7321).
• [3] Opilon monograph
• [4] BDDCS applied to over 900 drugs
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.
• [8] ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013 Aug;13(4):349-53.
• [9] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [10] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [11] The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. Pharmacopsychiatry. 2019 Sep;52(5):222-231.
• [12] O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
• [13] Cerner Multum, Inc. "Australian Product Information.".
• [14] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [15] Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
• [16] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
• [17] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
• [18] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [19] Canadian Pharmacists Association.
• [20] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [21] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [22] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [23] Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
• [24] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
• [25] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [26] Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
• [27] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [28] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
• [29] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [30] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [31] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
• [32] Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
• [33] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [34] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [35] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [36] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [38] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [39] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [40] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [41] Product Information. Effexor (venlafaxine). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [42] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [43] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [44] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [45] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [46] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [47] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [48] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [49] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [50] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [51] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [52] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [53] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [54] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [55] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [56] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [57] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [58] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
• [59] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [60] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [61] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [62] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [63] Cox R, Krupnick J, Bush N, Houpt A "Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder." J Miss State Med Assoc 41 (2000): 690-2. [PMID: 10974795]
• [64] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [65] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [66] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [67] Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
• [68] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [69] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [70] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [71] Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.